GRAFT POLYMER UK LS -001 (J4I) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GRAFT POLYMER UK LS -001 (J4I) has a cash flow conversion efficiency ratio of -0.048x as of November 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-149.00K ≈ $-174.20K USD) by net assets (€3.08 Million ≈ $3.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see J4I company net worth for the company's overall valuation and market capitalisation.
GRAFT POLYMER UK LS -001 - Cash Flow Conversion Efficiency Trend (2023–2026)
This chart illustrates how GRAFT POLYMER UK LS -001's cash flow conversion efficiency has evolved over time, based on yearly financial data.
GRAFT POLYMER UK LS -001 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GRAFT POLYMER UK LS -001 ranked by their cash flow conversion efficiency. See J4I operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ARB IOT Group Limited Ordinary Shares
NASDAQ:ARBB
|
0.055x |
|
Evergold Corp
V:EVER
|
-0.033x |
|
Canterbury Resources Ltd
AU:CBY
|
-0.060x |
|
Humax Holdings Co. Ltd
KQ:028080
|
0.092x |
|
Way 2 Vat Ltd
AU:W2V
|
-1.805x |
|
Lite Access Technologies Inc
V:LTE
|
1.235x |
|
Dovre Group Plc
HE:DOV1V
|
-0.559x |
|
Banaras Beads Limited
NSE:BANARBEADS
|
-0.026x |
Annual Cash Flow Conversion Efficiency for GRAFT POLYMER UK LS -001 (2023–2026)
The table below shows the annual cash flow conversion efficiency of GRAFT POLYMER UK LS -001 from 2023 to 2026. View current stock price of GRAFT POLYMER UK LS -001 for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-05-31 | €6.19 Million ≈ $7.24 Million |
€-3.27 Million ≈ $-3.83 Million |
-0.529x | -44.28% |
| 2025-05-31 | €3.08 Million ≈ $3.61 Million |
€-1.13 Million ≈ $-1.32 Million |
-0.366x | +40.04% |
| 2024-05-31 | €2.03 Million ≈ $2.37 Million |
€-1.24 Million ≈ $-1.45 Million |
-0.611x | -17.91% |
| 2023-05-31 | €4.55 Million ≈ $5.32 Million |
€-2.36 Million ≈ $-2.76 Million |
-0.518x | -- |
About GRAFT POLYMER UK LS -001
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre… Read more